Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
763.140.1%
QQQ
716.510.03%
BTC/USD
78381.000.1269%
DIA
524.880.15%
GLD
402.810.13%
TLT
81.680.06%

Eledon Pharmaceuticals Inc

ELDNNASDAQ
Trade with Public
Trade with Public
$2.82
-0.11-3.75%
At close: Sep 9, 5:00 PM EST
$2.88
0.06452.29%
After Hours: 7:35 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Eledon Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Eledon Pharmaceuticals (ELDN).

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

5Buy
Consensus RatingBuy# Analysts5Avg. Consensus PT$11Upside to Avg. PT+287.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 21, 2026Rodman & RenshawSeema SheoranInitiateBuy$12
Nov 18, 2025GuggenheimVamil DivanPT CutBuy$9→$8
More with Benzinga EdgeGet Access

Analyst Ratings News

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
Avi Kapoor

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
Avi Kapoor

PRO
Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Eledon Pharmaceuticals, Lowers Price Target to $8

Guggenheim analyst Vamil Divan maintains Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and lowers the price target from $9 to $8.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Eledon Pharmaceuticals, Maintains $9 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and maintains $9 price target.
Benzinga Newsdesk

PRO
Craig-Hallum Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12

Craig-Hallum initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved